Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy - Wikidata - wikimedia - TriplyDB

Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy

Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy

http://www.wikidata.org/entity/Q35640228

about

Rapalogs in cancer prevention: anti-aging or anticancer?GSK-3 as potential target for therapeutic intervention in cancer Advances in targeting signal transduction pathways Activating ESR1 mutations in hormone-resistant metastatic breast cancer.Occupational exposure to carcinogens: Benzene, pesticides and fibers (Review)Occupational exposure to pesticides as a possible risk factor for the development of chronic diseases in humans (Review)Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma.Requirement for the eIF4E binding proteins for the synergistic down-regulation of protein synthesis by hypertonic conditions and mTOR inhibition Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells.Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells The role of S6K1 in ER-positive breast cancer.Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels Mechanisms of dihydrotestosterone action on resveratrol-induced anti-proliferation in breast cancer cells with different ERα status.Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine Answering the ultimate question "what is the proximal cause of aging?"Recent discoveries in the cycling, growing and aging of the p53 field Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging.Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes.Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions.Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells.Adipose-derived Mesenchymal Stem Cells (ASCs) may favour breast cancer recurrence via HGF/c-Met signaling.Endocrine resistance in breast cancer.Altholactone Inhibits NF-κB and STAT3 Activation and Induces Reactive Oxygen Species-Mediated Apoptosis in Prostate Cancer DU145 Cells.Integrin α5β1 simultaneously controls EGFR-dependent proliferation and Akt-dependent pro-survival signaling in epidermoid carcinoma cells.Midkine confers Adriamycin resistance in human gastric cancer cells.miR-202 Suppresses Cell Proliferation by Targeting FOXR2 in Endometrial Adenocarcinoma.The selective inhibition of nuclear PKCζ restores the effectiveness of chemotherapeutic agents in chemoresistant cells.In vitro assessment of antitumor activities of the PI3K/mTOR inhibitor GSK2126458.Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells.Curcumin Suppresses the Colon Cancer Proliferation by Inhibiting Wnt/β-Catenin Pathways via miR-130a.Doxycycline inhibits breast cancer EMT and metastasis through PAR-1/NF-κB/miR-17/E-cadherin pathway.Virosecurinine induces apoptosis in human leukemia THP-1 cells and other underlying molecular mechanisms.A combination of curcumin and oligomeric proanthocyanidins offer superior anti-tumorigenic properties in colorectal cancer

P2860

Q26866151-A7D0A7D9-E90F-497F-80B7-DF10DF16AAB8 Q27013811-B988F8F8-FDD9-422C-A15E-E306C6DBEFEF Q27686983-B48507DB-0F24-45F0-BF3D-4666D4DB69B3 Q27852630-4E3A8470-E0C6-473C-AF10-A2A1490BEAD0 Q28393587-2630B638-5282-4180-BA6D-03CB2D6FF729 Q30244123-9B7FAAB5-6907-4166-A4CA-9BA255ABDF99 Q33572280-F1D5F4F0-BF5D-4A8E-966C-8480D61F8735 Q33917551-53E56A76-AFE3-4C1A-9785-CA63428CACA5 Q34164683-02368E26-8177-4B6D-8011-19CD457DEA12 Q34260622-5DAD121C-3029-448E-B8C4-59B00CB29894 Q34571141-9FCD656D-EEA4-4C22-9A1E-9B101EFA1C0D Q34936880-FE25FABA-4C79-44BC-8899-E87BD0799274 Q35640301-48AE6FF9-4778-4992-9C48-95352FD26644 Q35686894-8F694C41-4568-4B4D-9F3F-12735B06A166 Q36304094-BA9D289A-B3EE-4657-9C9E-0506D3AB9CCC Q36339232-C00179B4-399A-4D26-9EC9-51FC4FD40A4D Q36546496-1562BAF5-1B5F-4498-85B1-47612B49750F Q36556350-E97C1F95-63B4-48A8-BF0B-B8D47E23A706 Q36736351-68D6F447-DD05-47F5-A9BD-5407668B3F07 Q36736358-114FA44A-3C3E-4613-BA62-138465068EEE Q36736362-05C71F21-7D3E-4E1D-A6C1-7B0E5B80E59D Q36862768-13F1C159-0F7E-405B-8F69-45926B1BDD43 Q36926098-E132D6A4-B948-43DC-A19E-8203A209ECAA Q36926148-2B3E04A1-7B55-4C46-BE0F-603F7759F170 Q37030911-8D5A29E3-8D15-46EE-A1B5-0A920851839B Q37692593-BA060E05-B803-4B67-9D05-91B7C4EBCA53 Q37718453-21674E97-041B-4CD4-8214-78ADD67B53E7 Q38163573-830156C4-401C-4E60-9621-4CDB985676E0 Q38717326-72700B12-A5E8-42F6-BA28-BABCB20D99BA Q39342816-BDD541EE-80BD-4948-8051-5CFE48443528 Q39350211-815B22C1-BAC9-467A-8750-6374D8F7E019 Q41371230-D4649908-68CF-4091-BDEC-6361CD3A9716 Q42550749-F5CFF991-57AB-4FE9-B1A9-122AB55B06BB Q42934552-9B8986CB-6425-4442-BF9F-F4CF97D91201 Q47110143-1C4BBA41-2185-43AA-B9B5-AD99A67BE658 Q47136685-93C02B89-34F8-40B6-A3C7-7F51D4264348 Q47141937-FAA1F2AD-BDFA-4B98-B59A-54E55A4F854E Q49335200-55BB5673-3B25-4ABA-AFAA-FC88F8CC0D92 Q58740657-7AC8DDE5-2E19-46AD-802D-E44F12667697

P2860

Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy

http://www.wikidata.org/entity/Q35640228

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy

@ast

Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy

@en

type

label

Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy

@ast

Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy

@en

prefLabel

Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy

@ast

Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy

@en

P1433

Q35640228-E1651AEE-310F-481C-A79C-78A0B4866888

P1476

Q35640228-E80FCFA3-BFDD-4860-B7CF-45D3B0931C3A

P2093

Q35640228-05608AAF-8945-4E7D-A4E5-8655F600807C

Q35640228-0BCCC1C1-DDAA-414E-A84D-E9E2F9C7F699

Q35640228-3BCB864B-607A-4865-807B-CCE8CB4C5847

Q35640228-508FE0CA-937E-42DD-AD86-C0829F379E4B

Q35640228-5C0373AF-476C-4E9E-9BCD-CF044E010813

Q35640228-8971252C-3226-4631-8726-B869406ACC9E

Q35640228-8BA93E3B-66B5-4527-8C0D-3FD4CB650A46

Q35640228-970F54E3-5F4D-454D-BF2E-BFF692EA6D14

Q35640228-A1D9F791-4A7A-439F-934A-3FACB1C56090

Q35640228-D795815D-CD34-4BD0-8418-CC9943F13527

P2860

Q35640228-0307E40B-13B3-4C82-8796-72D42D18E831

Q35640228-084A8B36-39F5-4912-9033-BF6661D56BD9

Q35640228-09172544-BE3C-4A6C-A295-9D4542D231C7

Q35640228-0A9E5121-38D5-4E6A-8ADF-E874AAF53076

Q35640228-0E022CA1-F38F-40AE-BFDD-007811588390

Q35640228-0F65A38D-CAE1-422F-B8BC-F511EA40FEDA

Q35640228-12A3F6CA-4F7E-4777-97EF-1E22AD5196B6

Q35640228-15AD7D80-C2A8-4D94-9007-FA05D3038074

Q35640228-16EF6FD8-3E8B-4EAD-86D8-753EAAC9F34D

Q35640228-18778392-293D-4CB6-B7B7-DEF071291B0C

P304

Q35640228-B485A1D0-3424-4BD5-8D0A-F9B0F0A87F05

P31

Q35640228-8629FBB8-570B-4EB6-B57C-EB8C14D4B4F3

P356

Q35640228-755B8DA9-86BA-4E69-B44E-A46FFA04C8D1

P407

Q35640228-CCA40E7E-BA0B-448B-AA2B-6C83510649C2

P433

Q35640228-2EDB8B52-4DDA-4A67-AC7C-CF3EE3CAD6BC

P478

Q35640228-420E45D4-59AB-4FA7-A928-D7D29ABCA073

P577

Q35640228-C2718EE3-BCF1-476F-B377-107D22C0AF6A

P5875

Q35640228-FEDBD607-C1C0-46ED-83D5-BD22748941E3

P698

Q35640228-63E42BB5-A849-4580-BCE3-ABB59523BFDD

P932

Q35640228-D4EB548F-B258-471C-ADDA-0F352BCABD5A

P356

P1433

P1476

Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy

@en

P2093

Alberto M Martelli

http://www.w3.org/2001/XMLSchema#string

Ferdinando Nicoletti

http://www.w3.org/2001/XMLSchema#string

Franca Stivala

http://www.w3.org/2001/XMLSchema#string

James A McCubrey

http://www.w3.org/2001/XMLSchema#string

Kristin M Stadelman

http://www.w3.org/2001/XMLSchema#string

Linda S Steelman

http://www.w3.org/2001/XMLSchema#string

Lyudmyla B Drobot

http://www.w3.org/2001/XMLSchema#string

Massimo Libra

http://www.w3.org/2001/XMLSchema#string

Melissa L Sokolosky

http://www.w3.org/2001/XMLSchema#string

Richard A Franklin

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation

Potential use of rapamycin in HIV infection

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Multidrug resistance in cancer: role of ATP-dependent transporters

Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate

GSK3beta and aging liver.

Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.

Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.

Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair.

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.

P304

538-550

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.302

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51468444

http://www.w3.org/2001/XMLSchema#string

P698

21730367

http://www.w3.org/2001/XMLSchema#string

P932

3248182

http://www.w3.org/2001/XMLSchema#string